Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 24
Summary
- Conditions
- Acute Myelogenous Leukemia
- Advanced Myelodysplastic Syndromes
- AML
- MDS
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Dose escalation, traditional 3:3 designMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03459859
- Collaborators
- Takeda
- Investigators
- Principal Investigator: Justin Watts, MD University of Miami
Get Well Soon